Tesaro Inc (TSRO)

133.36
NASDAQ : Health Care
Prev Close 130.76
Day Low/High 128.33 / 134.17
52 Wk Low/High 29.51 / 148.74
Avg Volume 1.22M
Exchange NASDAQ
Shares Outstanding 53.41M
Market Cap 6.98B
EPS -6.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!

AstraZeneca Is Now a Competitive Threat to Tesaro in Ovarian Cancer Maintenance Therapy

AstraZeneca Is Now a Competitive Threat to Tesaro in Ovarian Cancer Maintenance Therapy

AstraZeneca's Lynparza significantly delayed the recurrence of tumors in patients with ovarian cancer compared to a placebo, according to results from a phase III study announced by the company Wednesday.

Closing Bell: Stocks Lifted by Oil Prices; Facebook Launches Work-Friendly Social Network

Closing Bell: Stocks Lifted by Oil Prices; Facebook Launches Work-Friendly Social Network

U.S. stocks closed higher Monday as oil prices gained steam and Wall Street looked ahead to the start of earnings season.

Stocks Buoyed by Higher Oil Prices; Investors Await Third-Quarter Earnings

Stocks Buoyed by Higher Oil Prices; Investors Await Third-Quarter Earnings

U.S. stocks are higher Monday thanks to a rally in crude oil.

Stocks Maintain Gains as Oil Rallies

Stocks Maintain Gains as Oil Rallies

U.S. stocks rise Monday as oil prices surge.

Trending Tickers: MRK, BMY, TSRO, TWLO, CRM

Trending Tickers: MRK, BMY, TSRO, TWLO, CRM

Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.

Even High-Flying Tesaro and Its Ovarian Cancer Drug Has a Bear Thesis. Here It Is, Explained

Even High-Flying Tesaro and Its Ovarian Cancer Drug Has a Bear Thesis. Here It Is, Explained

Tesaro is soaring, but the company is overvalued if regulators decide to grant marketing clearance for niraparib only in a smaller, more restricted population of ovarian cancer patients.

Tesaro (TSRO) Stock Soars on Ovarian Cancer Trial Success, Upgraded

Tesaro (TSRO) Stock Soars on Ovarian Cancer Trial Success, Upgraded

Tesaro's (TSRO) stock rating was lifted to 'buy' at Bank of America/Merrill Lynch.

Rev's Forum: News Flow Works Against the Bears Once More

Rev's Forum: News Flow Works Against the Bears Once More

Those who thought we were ready to break down look foolish again.

Analysts' Actions -- American Eagle, Mattel, Netflix, Tesaro and More

Analysts' Actions -- American Eagle, Mattel, Netflix, Tesaro and More

Here are Monday's top research calls, including upgrades for American Eagle, Mattel and Tesaro, and new coverage of Netflix.

Tesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial Shows

Tesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial Shows

Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.

Investor's Guide to This Week's Clovis, Tesaro Ovarian Cancer Drug Updates

Investor's Guide to This Week's Clovis, Tesaro Ovarian Cancer Drug Updates

A cancer research meeting beginning on Friday will provide investors with an opportunity to inspect updated clinical data on two competing PARP inhibitors from Clovis Oncology and Tesaro.

Is Tesaro Another M&A Target? The Charts Say It Is

Is Tesaro Another M&A Target? The Charts Say It Is

This stock could be headed for $120.

Is Bad News Necessarily a Bad Thing?

Big-cap names boost the market.